ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

PRCT PROCEPT BioRobotics Corporation

0.00
0.00 (0.00%)
Share Name Share Symbol Market Type
PROCEPT BioRobotics Corporation NASDAQ:PRCT NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0 -

PROCEPT BioRobotics to Present at the 44th Annual TD Cowen Health Care Conference in Boston

12/02/2024 9:05pm

GlobeNewswire Inc.


PROCEPT BioRobotics (NASDAQ:PRCT)
Historical Stock Chart


From Dec 2023 to Jun 2024

Click Here for more PROCEPT BioRobotics Charts.

PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 44th Annual TD Cowen Health Care Conference in Boston. Management is scheduled to present on Tuesday, March 5 at 12:50 p.m. Eastern Time. A live webcast of the event, as well as an archived recording, will be available on the “Investors” section of the company’s website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.

About PROCEPT BioRobotics CorporationPROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. The Company has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Investor Contact:Matt BacsoVP, Investor Relations and Business Operationsm.bacso@procept-biorobotics.com

1 Year PROCEPT BioRobotics Chart

1 Year PROCEPT BioRobotics Chart

1 Month PROCEPT BioRobotics Chart

1 Month PROCEPT BioRobotics Chart